

ACCELERON PHARMA INC  
Form 8-K  
June 24, 2014

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 20, 2014**

---

**ACCELERON PHARMA INC.**

(Exact name of Registrant as specified in its charter)

<b>Delaware</b>	<b>001-36065</b>	<b>27-0072226</b>
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)

<b>128 Sidney Street</b>	
<b>Cambridge, MA</b>	<b>02139</b>
(Address of principal)	(Zip Code)

Edgar Filing: ACCELERON PHARMA INC - Form 8-K

executive offices)

Registrant's telephone number, including area code: **(617) 649-9200**

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.07. Submission of Matters to a Vote of Security Holders**

On June 20, 2014, Acceleron Pharma Inc. (the Company) held its previously announced Annual Meeting of Stockholders (the Meeting), at which a quorum was present. At the Meeting, the stockholders of the Company voted on the two proposals as follows: (i) to elect Jean M. George, George Golumbeski and Edwin M. Kania as Class I members of the board of directors to serve until the Company's 2017 annual meeting of stockholders and until their successors are duly elected and qualified ( Proposal 1 ) and (ii) to ratify the selection of Ernst & Young, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2014 ( Proposal 2 ).

The Company's stockholders approved Proposal 1. The votes cast at the Annual Meeting were as follows:

- On the election of Jean M. George as a Class I director 24,171,606 shares voted for and 410,924 shares withheld.
- On the election of George Golumbeski as a Class I director 24,564,398 shares voted for and 18,132 shares withheld.
- On the election of Edwin M. Kania as a Class I director 24,577,358 shares voted for and 5,172 shares withheld.

There were no abstentions or broker non-votes with respect to Proposal 1.

The Company stockholders approved Proposal 2. The votes cast at the Annual Meeting were as follows: 24,567,927 shares voted for, 14,603 shares voted against and zero shares abstained from voting. There were no broker non-votes with respect to Proposal 2.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ACCELERON PHARMA INC.**

By: */s/ John Quisel*  
John Quisel  
Senior Vice President and General Counsel

Date: June 24, 2014